Cost-Utility of Rapid Polymerase Chain Reaction-Based Influenza Testing. for High-Risk Emergency Department Patients

被引:24
作者
Dugas, Andrea Freyer [1 ,2 ]
Coleman, Sara [2 ]
Gaydos, Charlotte A. [1 ,2 ,3 ]
Rothman, Richard E. [1 ,3 ]
Frick, Kevin D. [2 ]
机构
[1] Johns Hopkins Univ, Dept Emergency Med, Baltimore, MD 21218 USA
[2] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA
[3] Johns Hopkins Univ, Div Infect Dis, Dept Med, Baltimore, MD USA
关键词
NEURAMINIDASE INHIBITOR ZANAMIVIR; RANDOMIZED CONTROLLED-TRIAL; B VIRUS-INFECTIONS; UNITED-STATES; ANTIVIRAL THERAPY; OSELTAMIVIR TREATMENT; TREATING INFLUENZA; SEASONAL INFLUENZA; INHALED ZANAMIVIR; DECISION RULE;
D O I
10.1016/j.annemergmed.2013.01.005
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objective: We evaluate the cost-effectiveness of polymerase chain reaction (PCR)-based rapid influenza testing and treatment for influenza in adult emergency department (ED) patients who are at high risk for or have evidence of influenza-related complications. Methods: We developed a cost-utility decision analysis model that assessed adult patients presenting to the ED with symptoms of an acute respiratory infection, who met the Centers for Disease Control and Prevention criteria for recommended antiviral treatment. Analysis was performed from the societal perspective, with incremental comparisons of 4 influenza testing and treatment strategies: treat none, treat according to provider judgment, treat according to results of a PCR-based rapid diagnostic test, and treat all. Results: Treating no patients with antivirals was dominated by all other strategies that increased in both cost and benefit in the following order: treat according to provider judgment, treat according to results of a PCR-based rapid diagnostic test, and treat all. As influenza prevalence increases, treating all patients eventually dominated all other options. Conclusion: The economic benefit of incorporating use of rapid PCR-based influenza testing for ED patients at risk of developing influenza-related complications depends on influenza prevalence; treatment guided by physician diagnosis or rapid testing, and treatment of all patients is more effective and less costly than no treatment.
引用
收藏
页码:80 / 88
页数:9
相关论文
共 35 条
  • [1] American Medical Association, 2011, CURR PROC TERM COD 9
  • [2] [Anonymous], CONS PRIC IND
  • [3] [Anonymous], 2011, DRUG TOPICS RED BOOK
  • [4] Balish A., 2009, Morbidity and Mortality Weekly Report, V58, P826
  • [5] What does the value of modern medicine say about the $50,000 per Quality-Adjusted Life-Year decision rule?
    Braithwaite, R. Scott
    Meltzer, David O.
    King, Joseph T., Jr.
    Leslie, Douglas
    Roberts, Mark S.
    [J]. MEDICAL CARE, 2008, 46 (04) : 349 - 356
  • [6] Centers for Disease Control and Prevention, 2011, SEAS INFL
  • [7] Cox FM, 2000, AM J MANAG CARE, V6, P205
  • [8] Donner B, 2009, PHARMACOEPIDEM DR S, V20, P532
  • [9] Fiore Anthony E., 2011, Morbidity and Mortality Weekly Report, V60, P1
  • [10] Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients
    Griffin, AD
    Perry, AS
    Fleming, DM
    [J]. PHARMACOECONOMICS, 2001, 19 (03) : 293 - 301